QUICK BUY ALERT: TEMPUS (TEM)

As the market holds steady and with June over, we're back, and we've decided to bring a stock with us: Tempus (TEM).

Tempus is yet another AI play but with a twist. With the rapid growth of technology and our increasing understanding of genomic data in the healthcare industry, physicians are tasked with remembering and applying an ever-expanding amount of information that is constantly evolving. Tempus AI aims to consolidate this information throughout the entire medical field, whether it involves an AI-powered health concierge for patients, an AI assistant for physicians, or a system that helps pharmaceutical companies and clinicians identify the best patients for clinical studies. The technology they're developing aims to help people in these fields by reducing workloads and consolidating data, eliminating some of the strain felt by those working such essential jobs.

We believe in this vision, and with their impressive results and rapidly stabilizing earnings per share, we believe this company will be a long-term success.

We've purchased Tempus (TEM) at $59.73.